Danaher Corporation (ETR:DAP)
Germany · Delayed Price · Currency is EUR | Market Cap | 100.33B -18.6% |
| Revenue (ttm) | 21.51B +4.0% |
| Net Income | 3.20B -2.0% |
| EPS | 4.49 +0.4% |
| Shares Out | n/a |
| PE Ratio | 31.33 |
| Forward PE | 19.22 |
| Dividend | 1.15 (0.81%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 1,442 |
| Average Volume | 914 |
| Open | 141.60 |
| Previous Close | 142.65 |
| Day's Range | 139.80 - 141.70 |
| 52-Week Range | 139.80 - 208.30 |
| Beta | 0.84 |
| RSI | 27.64 |
| Earnings Date | Apr 21, 2026 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial numbers in USD Financial StatementsNews
Danaher Transcript: Bank of America Global Healthcare Conference 2026
Solid first quarter with 300 basis points of core growth, strong bioprocessing and diagnostics momentum, and robust performance in life sciences. Guidance for 3%-6% organic growth is maintained, with headwinds expected to fade and capital deployment focused on M&A and strategic investments.
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Heal...
Danaher Announces Quarterly Dividend
WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stoc...
Danaher Transcript: AGM 2026
The meeting covered director elections, auditor reappointment, executive compensation, and incentive plan approval, all passing with strong majorities. Financial results showed $24.6B in revenue, high margins, and strong recurring revenue, with a focus on life sciences and diagnostics.
Masimo shareholders approve acquisition by Danaher
Masimo (MASI) announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo,…
Masimo Shareholders Approve Acquisition by Danaher
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...
Agilent appoints Michael Buckner as CLO
Agilent Technologies (A) announced the appointment of Michael Buckner as chief legal officer. Buckner joins Agilent from Danaher Corp. (DHR), where he served as vice president, deputy general counsel,...
Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook
Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and life-sciences company of defrauding them by overstating demand for its equipment as the worst of the COV...
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €...
Danaher price target lowered to $250 from $270 at UBS
UBS lowered the firm’s price target on Danaher (DHR) to $250 from $270 and keeps a Buy rating on the shares. The firm still sees potential upside despite respiratory headwinds,…
Danaher price target lowered to $245 from $249 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Danaher (DHR) to $245 from $249 and keeps an Outperform rating on the shares. The firm updated its model…
Danaher price target lowered to $235 from $275 at Guggenheim
Guggenheim analyst Subbu Nambi lowered the firm’s price target on Danaher (DHR) to $235 from $275 and keeps a Buy rating on the shares. Q1 results were about as the…
Danaher price target raised to $245 from $240 at Jefferies
Jefferies analyst Tycho Peterson raised the firm’s price target on Danaher (DHR) to $245 from $240 and keeps a Buy rating on the shares after a “solid” Q1 report. Headwinds…
Danaher Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution, with core revenue up 0.5% and adjusted EPS up 9.5% year-over-year. Bioprocessing and life sciences offset respiratory headwinds, and the Masimo acquisition is expected to be accretive. Full-year guidance was raised for adjusted EPS.
Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
Danaher boosted the upper end of its full-year earnings guidance, following a first-quarter beat fueled by double-digit momentum in its Biotechnology and Life Sciences segments.
Danaher beats first-quarter profit estimates on strong bioprocessing demand
Life sciences firm Danaher topped first-quarter profit expectations on Tuesday, fueled by strong demand for its bioprocessing tools used in drug manufacturing, lifting shares 2% in premarket trading.
Options Volatility and Implied Earnings Moves Today, April 21, 2026
Today, several major companies are expected to report earnings: 3M (MMM), Annaly Capital (NLY), Danaher (DHR), GE Aerospace (GE), Halliburton (HAL), Intuitive Surgical (ISRG), Northrop Grumman (NOC), ...
Danaher reports Q1 adjusted EPS $2.06, consensus $1.94
Reports Q1 revenue $6B, consensus $6B. Rainer Blair, President and CEO, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and…
Danaher sees Q2 non-GAAP core revenue up in LSD percentage range y/y
For the second quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.
Danaher raises FY26 adjusted EPS view to $8.35-$8.55 from $8.35-$8.50
Consensus $8.40. For full year 2026, the Company continues to expect that non-GAAP core revenue will increase in the 3% to 6% range year-over-year, consensus $25.62B. The Company is also…
Danaher Reports First Quarter 2026 Results
WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and perio...
Danaher price target lowered to $249 from $251 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Danaher (DHR) to $249 from $251 and keeps an Outperform rating on the shares. The firm updated its model…
Danaher price target lowered to $205 from $220 at Rothschild & Co Redburn
Rothschild & Co Redburn lowered the firm’s price target on Danaher (DHR) to $205 from $220 and keeps a Neutral rating on the shares. The firm expects the company’s exposure…
Danaher price target lowered to $230 from $250 at Barclays
Barclays lowered the firm’s price target on Danaher (DHR) to $230 from $250 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing BREA, Calif., April 13, 20...